CareDx, Inc. (CDNA) Form 10-Q — Jul 30, 2026
CareDx reported record financial results for the second quarter of 2026, with total revenue increasing 52% year-over-year to $131.9 million driven by a 61% surge in testing services revenue. The company posted a net income of $110.6 million, or $2.15 per share, a significant turnaround from the net loss of $8.6 million in the prior year period. The profitability was largely fueled by the completion of the sale of its lab products business to Eurobio Scientific S.A. for $171.7 million in cash, which resulted in a $113 million gain on sale.
Key figures
- Eps
- 2.15
- Revenue
- 131,948,000
- Net Income
- 110,636,000
- Revenue Yoy
- 52%
- Cash Position
- 373,636,000
- Shares Outstanding
- 51,734,223
- Acquisition cost naveris
- 161,800,000
- Testing services revenue
- 99,927,000
- Testing services volume growth
- 17%
- Contingent consideration naveris
- 100,000,000
- Gain on sale lab products business
- 112,966,000
- Proceeds from sale lab products business
- 171,700,000
Price after filing
Close on the filing date to close N calendar days later (from $35.75). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.